Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
World Sleep 2022
ACTRIMS 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Fremanezumab
5:33
Real-world studies of CGRP monoclonal antibodies and gepants for migraine
Chia-Chun Chiang
• 3 Apr 2022
4:00
Comparing CGRP ligand- and receptor-directed antibody treatments in migraine
Piero Barbanti
• 27 Sep 2021
2:52
Is the CGRP ligand or receptor a better target in migraine?
Oved Daniel
• 24 Sep 2021
1:47
Approval of anti-CGRP monoclonal antibodies for migraine in Japan
Koichi Hirata
• 10 Sep 2021
1:23
Real-world effectiveness of fremanezumab for migraine prevention
Dimos-Dimitrios Mitsikostas
• 15 Jun 2021
3:02
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant
Jessica Ailani
• 18 Apr 2021
20:54
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic
Stewart Tepper
• 24 May 2020
2:52
Fremanezumab in patients with chronic or episodic migraine
Uwe Reuter
• 22 May 2020
3:16
PEARL study: fremanezumab for chronic or episodic migraine in the real world
Messoud Ashina
• 29 May 2020
